Skip to main content

Table 3 Relationship between mRNA levels of 20 markedly upregulated genes and breast cancer progression

From: Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy

Genes Normal breast tissues
(n = 9)
Benign breast tumors
(n = 14)
pa DCIS of the breast
(n = 14)
pb Invasive grade I breast tumors
(n = 11)
pc Invasive grade III breast tumors
(n = 12)
pd
NDC80 1,0 (0,00-1,39) 3,64 (1,32-17,79) e < 0,01 14,55 (4,10-24,20) 0,0009 7,11 (1,38-13,55) NS 15,22 (4,76-54,69) 0,01
BUB1 1,0 (0,00-1,38) 2,97 (1,52-14,03) < 0,01 15,37 (1,59-94,35) 0,001 6,59 (0,00-94,35) NS 17,54 (5,46-57,28) 0,004
BUB1B 1,0 (0,24-2,97) 2,72 (1,01-9,38) < 0,01 14,54 (3,53-39,95) 0,0002 6,11 (0,00-11,31) NS 18,66 (2,39-105,05) 0,004
CCNB1 1,0 (0,00-3,14) 2,51 (1,01-6,82) < 0,01 6,82 (1,71-15,24) 0,002 4,23 (1,33-5,90) NS 9,05(3,51-41,64) 0,007
TACC3 1,0 (0,00-1,35) 1,70 (0,78-6,18) < 0,01 7,21 (1,77-13,67) 0,0003 5,31 (1,11-11,24) 0,02 17,04 (4,98-74,03) 0,0006
TPX2 1,0 (0,31-4,23) 2,84 (0,82-10,73) < 0,05 16,99 (4,70-35,59) 0,00009 6,51 (1,67-19,74) NS 23,84 (6,15-315,17) 0,0009
CCNA2 1,0 (0,05-1,45) 2,19 (0,20-7,19) < 0,05 10,56 (1,70-17,21) 0,0006 3,36 (1,04-8,34) NS 11,38 (1,64-104,33) 0,008
CDC2 1,0 (0,00-2,11) 1,76 (0,76-7,36) < 0,05 10,16 (2,56-20,87) 0,00008 6,01 (1,06-10,78) NS 10,99 (3,32-56,75) 0,006
CDC20 1,0 (0,06-1,28) 1,67 (0,63-3,54) < 0,05 3,90 (1,49-14,09) 0,0001 1,65 (1,76-3,00) NS 6,14 (1,76-142,68) 0,0002
NEK2 1,0 (0,16-2,87) 1,17 (0,41-3,78) NS 10,44 (2,03-26,23) 0,00004 2,67 (1,15-11,88) 0,008 14,83 (3,60-115,09) 0,0006
AURKA 1,0 (0,30-2,58) 1,12 (0,33-2,32) NS 6,04 (1,27-21,01) 0,00002 2,54 (1,25-7,16) 0,002 7,82 (2,04-58,89) 0,003
PLK1 1,0 (0,30-2,08) 0,80 (0,34-1,99) NS 3,83 (1,09-11,37) 0,00003 1,91 (0,20-5,66) 0,04 7,09 (1,92-117,27) 0,0009
TTK 1,0 (0,01-7,32) 2,43 (0,00-11,29) NS 9,85 (2,59-32,07) 0,0003 2,32 (0,00-5,68) NS 8,59 (4,14-55,84) 0,0002
AURKB 1,0 (0,00-3,24) 2,07 (0,22-7,41) NS 5,97 (0,99-26,91) 0,02 4,24 (1,05-10,06) NS 16,26 (5,70-210,84) 0,0003
BIRC5 1,0 (0,46-3,40) 1,37 (0,39-6,06) NS 7,86 (1,68-40,50) 0,00008 3,51 -0,54-7,29) NS 12,20 (3,14-128,0) 0,0007
ZWINT 1,0 (0,00-3,71) 1,98 (0,39-4,53) NS 5,70 (2,45-15,74) 0,0002 3,59 (0,89-6,09) NS 10,95 (2,70-55,46) 0,001
CCNB2 1,0 (0,31-1,93) 1,43 (0,70-5,98) NS 8,98 (1,57-23,43) 0,0002 3,31 (0,03-7,31) NS 12,28 (1,53-52,35) 0,005
CENPE 1,0 (0,03-4,58) 0,96 (0,33-6,15) NS 3,61 (1,11-8,34) 0,002 2,00 (0,33-5,57) NS 2,98 (0,84-10,15) 0,04
UBD 1,0 (0,00-3,07) 1,49 (0,34-4,66) NS 3,19 (0,43-4,66) 0,04 2,92 (0,19-14,72) NS 5,30 (1,16-32,37) NS
CCNB3 1,0 (0,00-6,11) 2,52 (0,53-5,82) NS 1,36 (0,00-8,94) NS 3,24 (0,63-8,54) NS 2,71 (0,00-8,54) NS
MKI67 1,0 (0,03-2,87) 2,63 (0,47-12,70) NS 14,92 (2,12-33,98) 0,0007 5,21 (0,13-12,15) NS 14,09 (2,45-189,14) 0,009
  1. aMann et Whitney's U Test: Benign breast tumors vs Normal breast tissues. NS, not significant.
  2. bDuctal Carcinoma In Situ (DCIS) of the breast vs Benign breast tumors.
  3. cInvasive grade I breast tumors vs Benign breast tumors.
  4. dInvasive grade III breast tumors vs Invasive grade I breast tumors.
  5. eMedian (range) of gene mRNA levels. The mRNA levels of the tumor samples were normalized such that the median of the 9 normal breast tissues mRNA levels was 1.